The collaboration makes 20/20 BioLabs’ AI-powered cancer screening tool available to a network of 40,000 practitioners.

20/20 BioLabs, Inc announced that its OneTest for Cancer is now available through the Evexia Diagnostics platform, a marketplace for functional and integrative medicine practitioners. The collaboration expands the reach of the laboratory-based blood test to Evexia’s network of approximately 40,000 clinicians across the US.

The OneTest for Cancer is an artificial intelligence-powered multi-cancer early detection (MCED) test designed for the detection and prevention of various cancers. By joining the platform, the test is positioned to reach a larger audience through a channel already integrated into clinical workflows.

“Making our testing solutions available through Evexia is an important commercial step for 20/20 BioLabs,” says Jonathan Cohen, chief executive officer of 20/20 BioLabs, in a release. “Evexia has built a highly efficient platform that connects innovative diagnostics companies with a large network of engaged practitioners.”

Clinical Utility and Monitoring

The test identifies specific biomarkers and quantifies their levels, which allows clinicians and patients to establish a personalized baseline and monitor changes over time. According to the companies, this capability makes the test a tool for proactive care and long-term health tracking.

“After a thorough evaluation of available MCED options, we selected OneTest for its combination of affordability and strong sensitivity for earlier-stage cancers,” says Ryan Obermeier, chief commercial officer at Evexia Diagnostics, in a release. “What truly sets this test apart is its ability to identify specific biomarkers and quantify their levels.”

Laboratory Standards and Technology

The tests are processed in a College of American Pathologists accredited and Clinical Laboratory Improvement Amendments-licensed laboratory located in Gaithersburg, MD. The company also plans to launch OneTest for Longevity, which measures inflammatory biomarkers, in the first half of 2026.

The partnership aims to support greater exposure for the testing solutions while providing practitioners with access to tools designed to inform earlier and more personalized care decisions. Evexia, founded in 2007, provides laboratory services designed for both licensed and non-licensed-to-order clinicians to enhance client efficiency and profitability.

ID 255091942 © Luisfilipemoreira | Dreamstime.com

Related Reading: